博拓生物
(688767)
| 流通市值：54.54亿 | | | 总市值：54.54亿 |
| 流通股本：1.49亿 | | | 总股本：1.49亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 312,178,379.69 | 214,684,129.57 | 89,376,734.08 | 448,012,337.89 |
| 营业收入 | 312,178,379.69 | 214,684,129.57 | 89,376,734.08 | 448,012,337.89 |
| 二、营业总成本 | 331,930,411.12 | 236,469,943.71 | 103,998,265.43 | 415,659,935.1 |
| 营业成本 | 166,581,363.38 | 113,664,093.39 | 46,871,801.51 | 241,784,295.48 |
| 税金及附加 | 3,608,057.63 | 2,716,836.23 | 1,789,569.27 | 8,381,523.89 |
| 销售费用 | 23,611,381.24 | 15,845,016.3 | 7,074,785.7 | 38,301,313.93 |
| 管理费用 | 46,403,198.75 | 32,704,396.79 | 16,303,409.4 | 59,337,452.27 |
| 研发费用 | 66,433,736.19 | 51,217,072.05 | 21,667,249.89 | 83,480,812.63 |
| 财务费用 | 25,292,673.93 | 20,322,528.95 | 10,291,449.66 | -15,625,463.1 |
| 其中:利息费用 | 647,580.2 | 189,809.12 | - | - |
| 其中:利息收入 | 24,161,019.82 | 16,596,895.46 | 8,604,291.66 | 38,271,318.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 483,420.04 | 353,518.3 | 122,764.95 | 320,319.1 |
| 加:投资收益 | -2,392,835.38 | -1,554,820.42 | -1,071,352.28 | 3,969,405.85 |
| 资产处置收益 | 37,951.89 | -8,531.25 | -12,988.22 | 247,488.75 |
| 资产减值损失(新) | -4,359,954.55 | -1,959,553.85 | -677,481.74 | -5,763,033.17 |
| 信用减值损失(新) | 368,601.19 | -818,189.03 | -128,920.64 | 236,841.77 |
| 其他收益 | 2,583,755.23 | 1,683,659.11 | 1,746,631.05 | 19,161,459.81 |
| 四、营业利润 | -23,031,093.01 | -24,089,731.28 | -14,642,878.23 | 50,524,884.9 |
| 加:营业外收入 | 616,936.03 | 609,077.93 | 226,349.81 | 72,564.57 |
| 减:营业外支出 | 986,646.97 | 141,987.07 | 7,311.41 | 915,782.36 |
| 五、利润总额 | -23,400,803.95 | -23,622,640.42 | -14,423,839.83 | 49,681,667.11 |
| 减:所得税费用 | -5,596,541.22 | -6,528,120.74 | -3,891,602.13 | 2,554,832.19 |
| 六、净利润 | -17,804,262.73 | -17,094,519.68 | -10,532,237.7 | 47,126,834.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -17,804,262.73 | -17,094,519.68 | -10,532,237.7 | 47,126,834.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -16,667,771.29 | -16,552,564.41 | -10,207,874.77 | 49,253,408.24 |
| 少数股东损益 | -1,136,491.44 | -541,955.27 | -324,362.93 | -2,126,573.32 |
| 扣除非经常损益后的净利润 | -22,297,208.75 | -20,801,885.17 | -12,946,986.22 | 27,001,186.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.11 | -0.11 | -0.07 | 0.34 |
| (二)稀释每股收益 | -0.11 | -0.11 | -0.07 | 0.34 |
| 八、其他综合收益 | 1,324,449.71 | 754,523.45 | 302,036.41 | 297,744.75 |
| 归属于母公司股东的其他综合收益 | 1,320,054.08 | 751,864.63 | 300,589.89 | 295,932.41 |
| 九、综合收益总额 | -16,479,813.02 | -16,339,996.23 | -10,230,201.29 | 47,424,579.67 |
| 归属于母公司股东的综合收益总额 | -15,347,717.21 | -15,800,699.78 | -9,907,284.88 | 49,549,340.65 |
| 归属于少数股东的综合收益总额 | -1,132,095.81 | -539,296.45 | -322,916.41 | -2,124,760.98 |
| 公告日期 | 2026-10-30 | 2026-08-29 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |